Navigation Links
Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
Date:12/2/2010

SCHAUMBURG, Ill., Dec. 2, 2010 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA approval and launch of its topotecan hydrochloride for injection, a chemotherapy agent, in conjunction with the innovator's patent expiry.  Sagent's topotecan is available in 4 mg single-dose latex-free vials.  This is the latest product to feature Sagent's proprietary PreventIV Measures™ packaging and labeling that is designed to aid in product differentiation and to help with the reduction of medication errors.  According to 2010 IMS data, the U.S. market for injectable topotecan approximated $158 million.

"Topotecan is an important treatment for patients who have recurrent small cell lung cancer sensitive disease or cervical cancer," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Our launch of topotecan reinforces Sagent's commitment to grow our oncology portfolio, to meet the needs of oncology patients and clinicians and to demonstrate our capabilities and expertise in injectable pharmaceuticals."

About Topotecan Hydrochloride for Injection

Topotecan is indicated for the treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy.  Additionally, topotecan in combination with cisplatin is indicated for the treatment of stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indications, complete side effect profile, boxed warnings and prescribing information.

About PreventIV Measures™

PreventIV Measures™ is Sagent's comprehensive, user-driven and patient-centered approach to product labeling and packaging
'/>"/>

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
9. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
10. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
11. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UNION CITY, Calif., Oct. 21, 2014 Abaxis, ... company manufacturing point-of-care blood analysis systems, today reported financial ... 2014. Second quarter overview: , Revenues ... quarter. , Diluted EPS of $0.24, up 33% ... , Service revenues from Abaxis Veterinary Reference Laboratories ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a ... the face, it certainly can be difficult to choose the ... extra favor by doing it the healthy way? Set aside ... to your body, exercise regularly, and choose foods with the ... weight; you need to exercise more and eat less. Despite ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... a booth at the American Foundation for Suicide Prevention’s ... The AFSP is a not-for-profit organization that hosts hundreds ... proceeds from these events are used to help understand ... education and personal relationships as well. , The ...
Breaking Medicine News(10 mins):Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... polio immunization campaign in Somalia, that will aim at vaccinating ... // ,The Head Honcho of WHO's Global Polio ... that the number of cases of polio are now beginning ... of the country which is a very difficult part of ...
... research team from Georgia Institute of Technology has developed ... (ATP) release and its role in cystic fibrosis. // ... and nano-electrodes to the tip of an atomic force ... monitor topography along with electrochemical activity at the cell ...
... down. The industry across the country is now facing a suicide ... the country, small farmers are scared due to low prices. // ... Rs 5 for one kg of chicken from Rs 1.80 and ... being forced to commit suicide. K Narayana Reddy, president, of Andhra ...
... study in Australia has found that babies born to women, ... birth weight and lower APGAR scores and are more likely ... women have a higher number of previous pregnancies, smoke more ... to the study in the April issue of Alcoholism: Clinical ...
... clot formation in both men and women according to a new ... cell testing in both sexes with 81 milligrams of acetyl salicylic ... platelets – the clot-forming cells. Clots in blood vessels of the ... while the drug's overall effects on blood cell function were the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Use Of Alcohol During Pregnancy Affects Newborns 2Health News:Low-dose Aspirin Benefits Both Sexes 2Health News:Low-dose Aspirin Benefits Both Sexes 3Health News:Low-dose Aspirin Benefits Both Sexes 4
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Handheld Digital Retinal Camera...
Inquire...
Specifically for placing follicular units....
Medicine Products: